- Jazz Pharmaceuticals (NASDAQ:JAZZ): Q3 Non-GAAP EPS of $4.31 beats by $0.23; GAAP EPS of $2.64 misses by $0.31.
- Revenue of $600.89M (+11.8% Y/Y) beats by $23.27M.
- Raises 2020 Guidance: Revenues: $2.32B - 2.38B; Total net product sales: $2.3B - 2.36B; Adj. gross margin: 94%; EPS: $3.70 - 4.85; non-GAAP EPS: $12.20 - 13.00.
- Press Release
- https://seekingalpha.com/news/3629954-jazz-pharmaceuticals-eps-beats-0_23-beats-on-revenue
Monday, November 2, 2020
Jazz Pharmaceuticals EPS beats by $0.23, beats on revenue
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.